Wedbush maintains Ultragenyx Pharma neutral, cuts $23 target
Wedbush maintains a neutral rating on Ultragenyx Pharma and cuts its price target to $23.00 from $30.00, according to Benzinga ratings action summarized by TradingView News.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.